Literature DB >> 23800827

SUNCT/SUNA and neurovascular compression: new cases and critical literature review.

Valentina Favoni1, Daniela Grimaldi, Giulia Pierangeli, Pietro Cortelli, Sabina Cevoli.   

Abstract

BACKGROUND: Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache with cranial autonomic symptoms (SUNA) are primary headache syndromes. A growing body of literature has focused on brain magnetic resonance imaging (MRI) evidence of neurovascular compression in these syndromes.
OBJECTIVE: The objective of this article is to assess whether SUNCT is a subset of SUNA or whether the two are separate syndromes and clarify the role of neurovascular compression.
METHOD: We describe three new SUNCT cases with MRI findings of neurovascular compression and critically review published SUNCT/SUNA cases.
RESULTS: We identified 222 published SUNCT/SUNA cases. Our three patients with neurovascular compression added to the 34 cases previously described (16.9%). SUNCT and SUNA share the same clinical features and therapeutic options. At present, there is no available abortive treatment for attacks. Lamotrigine was effective in 64% of patients; topiramate and gabapentin in about one-third of cases. Of the 34 cases with neurovascular compression, seven responded to drug therapies, 16 patients underwent microvascular decompression of the trigeminal nerve (MVD) with effectiveness in 75%.
CONCLUSIONS: We suggest that SUNCT and SUNA should be considered clinical phenotypes of the same syndrome. Brain MRI should always be performed with a dedicated view to exclude neurovascular compression. The high percentage of remission after MVD supports the pathogenetic role of neurovascular compression.

Entities:  

Keywords:  SUNA; SUNCT; autonomic; microvascular decompression; neurovascular compression

Mesh:

Year:  2013        PMID: 23800827     DOI: 10.1177/0333102413494273

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  13 in total

1.  Trigeminal neuralgia or SUNA/SUNCT: a dilemma unresolved.

Authors:  Vimal Kumar Paliwal; Ravi Uniyal; Durgesh Kumar Gupta; Zafar Neyaz
Journal:  Neurol Sci       Date:  2015-04-24       Impact factor: 3.307

Review 2.  The pathophysiology of the trigeminal autonomic cephalalgias, with clinical implications.

Authors:  Mads C J Barloese
Journal:  Clin Auton Res       Date:  2017-09-23       Impact factor: 4.435

Review 3.  Epicrania Fugax.

Authors:  María Luz Cuadrado; Angel L Guerrero; Juan A Pareja
Journal:  Curr Pain Headache Rep       Date:  2016-04

Review 4.  SUNCT/SUNA: A Review.

Authors:  Jared L Pomeroy; Stephanie J Nahas
Journal:  Curr Pain Headache Rep       Date:  2015-08

Review 5.  [Update on trigeminal autonomic cephalalgia].

Authors:  C Gaul; D Holle; A May
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

Review 6.  SUNCT and SUNA: an Update and Review.

Authors:  Karissa N Arca; Rashmi B Halker Singh
Journal:  Curr Pain Headache Rep       Date:  2018-06-21

Review 7.  Symptomatic Trigeminal Autonomic Cephalalgias.

Authors:  Ilse F de Coo; Leopoldine A Wilbrink; Joost Haan
Journal:  Curr Pain Headache Rep       Date:  2015-08

8.  The temporal evolution of a facial pain syndrome associated with neurovascular contact: a case report.

Authors:  Sabrina Khan; Ida Wibrandt; Per Rochat; Messoud Ashina
Journal:  J Headache Pain       Date:  2015-02-11       Impact factor: 7.277

9.  Botulinum Toxin A for the Treatment of a Child with SUNCT Syndrome.

Authors:  Yi Zhang; Haifeng Zhang; Ya-Jun Lian; Yun-Qing Ma; Nan-Chang Xie; Xuan Cheng; Lu Zhang
Journal:  Pain Res Manag       Date:  2016-04-06       Impact factor: 3.037

10.  Shortlasting, Unilateral, Neuralgiform, Headache Attacks With Conjunctival Injection, Tearing, Sweating and Rhinorrhea: The Term and New View Points

Authors:  Fabio Antonaci; Torbjørn Fredriksen; Juan A Pareja; Ottar Sjaastad
Journal:  Front Neurol       Date:  2018-04-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.